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Abstract: Adult hippocampal neurogenesis (ahNG) occurs in the human brain. Adult gener-
ated neurons have been proposed to functionally contribute to relevant hippocampal functions 
such as learning and memory, mood regulation, and stress response. Learning, environmental 
enrichment, and physical exercise exert positive effects on ahNG. In parallel, these proneu-
rogenic stimuli have been shown to ameliorate cognitive performance and/or depressive-like 
behavior in animal models. Conversely, aging, social isolation, and chronic stress exert nega-
tive effects on ahNG. Interestingly, reduction of hippocampal neurogenesis is suggested to 
potentially contribute to cognitive decline and mood alterations associated with aging and 
several neuropsychiatric disorders. Clinical observation demonstrates that patients affected 
by chronic pain often exhibit increased anxiety and depression, impaired cognitive flexibility, 
and memory capacities. As of today, our understanding of the molecular and cellular events 
that may underlie the comorbidity of chronic pain, depression, and cognitive impairment is 
limited. Herein we review recent preclinical data suggesting that chronic pain may induce pro-
found changes in hippocampal plasticity, including reduced ahNG. We discuss the possibility 
that deregulated hippocampal neurogenesis in chronic pain may, at least in part, contribute to 
cognitive and mood alterations. Based on this hypothesis, the mechanisms underlying chronic 
pain-associated changes in hippocampal neurogenesis and related functions need to be addressed 
experimentally. One interesting feature of ahNG is its susceptibility to pharmacological modu-
lation. Again, based on preclinical data we discuss the possibility that, at least in principle, 
distinct analgesic drugs commonly used in chronic pain states (typical and atypical opiates, 
a2δ ligands, and acetyl-l-carnitine) may differentially impact ahNG and that this aspect could 
be taken into account to reduce and/or prevent the potential risk of cognitive and emotional 
side effects in the clinical setting.
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Function, dysfunction, and modulation of adult 
hippocampal neurogenesis
Throughout life, new neurons are generated in the dentate gyrus (DG) of the adult 
mammalian brain, a process referred to as adult hippocampal neurogenesis (ahNG). In 
that hippocampal region, the SubGranular Zone (SGZ) acts indeed as neurogenic niche, 
a permissive and instructive microenvironment where adult neural stem/progenitor 
cells (aNSC/NPC) survive, self-renew, and give rise to intermediate progenitor cells 
which, in turn, can generate neuroblasts capable of terminal neuronal differentiation. 
The surviving adult-born cells will eventually become granule neurons and will be 
functionally integrated into the DG preexisting circuit.1–4
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During the last two decades, extensive research efforts 
contributed to the concept that adult-born neurons may play a 
crucial role in several hippocampal-related functions, includ-
ing selected cognitive functions, pattern discrimination, mood 
regulation, and stress response.5–10 It is also of great interest 
that ahNG appears deregulated in several neurodegenerative 
and neuropsychiatric disorders, including major depressive 
disorder (MDD).11–13
ahNG is a remarkably modulable process. In animal 
models, learning, environmental enrichment (EE), and physi-
cal exercise have been shown to produce positive effects on 
proliferation and differentiation of aNSC/NPC as well as sur-
vival of their progeny. In parallel, these proneurogenic stimuli 
ameliorate cognitive performance or anhedonia in animal 
models of cognitive impairment or stress-induced depressive-
like behavior.14,15 On the contrary, aging and chronic stress 
exert negative effects on ahNG.16–18 Intriguingly, reduction of 
hippocampal neurogenesis has been proposed to potentially 
contribute to cognitive decline and mood alterations associ-
ated with aging and neuropsychiatric disorders.11–13
ahNG is also highly susceptible to pharmacological 
modulation. Antidepressant drugs increase hippocampal 
neurogenesis in rodents,19–22 and an increased number of 
hippocampal NPC and granule neurons are reported in post-
mortem brain of MDD patients undergoing antidepressant 
therapy.23–25 In addition, several experimental studies dem-
onstrate that antidepressants can counteract the inhibitory 
effect of stress on ahNG in rodent models of depressive-like 
disorder.12,26 Although still debated, it has been proposed 
that ahNG may be required for some behavioral effects of 
antidepressants in preclinical models and may potentially 
contribute to the antidepressant activity of these drugs also 
in the clinical setting.27,28 Emerging evidence also suggest 
that other psychoactive drugs, including the analgesic 
morphine and several drugs of abuse, result in molecular 
changes that may negatively affect different aspects of 
ahNG.29–31 Also these findings have important clinical 
implications since they raise the possibility that cognitive 
dysfunction and/or mood alteration in the setting of such 
drug use and/or abuse may, at least in part, be correlated 
with alterations in ahNG.13
Deregulated hippocampal 
neurogenesis in chronic pain states
As listed in Table 1, in rodent models, several preclinical 
studies have demonstrated a correlation between persistent 
pain and reduced hippocampal neurogenesis or blunted 
response of hippocampal NPC to proneurogenic stimuli.32–37 
Since chronic stress is a well-known negative regulator of 
ahNG, one may suggest that disrupted ahNG in chronic pain 
could be merely due to the stress associated with prolonged 
pain sufferance. On the other hand, it has been convincingly 
demonstrated that chronic immobilization stress exacerbates 
the deleterious effects of chronic pain on ahNG, in particular 
on proliferation and survival of newly generated cells.36 In a 
very elegant study, Mutso et al further investigated abnormali-
ties in hippocampal functioning in a persistent pain state.34 
Compared to sham-operated animals, neuropathic mice were 
proven unable to extinguish contextual fear and displayed 
increased anxiety-like behavior. Additionally, neuropathic 
mice displayed decreased hippocampal neurogenesis and 
altered short-term synaptic plasticity.34 Intriguingly, the same 
authors extended their observations to three distinct chronic 
pain patient subpopulations affected by osteoarthritis (OA), 
complex regional pain syndrome (CRPS), and chronic back 
pain (CBP). Compared with controls, CBP and CRPS, but 
not OA patients, had significantly reduced hippocampal vol-
ume bilaterally. Altogether, these findings prompted authors 
to suggest that hippocampus-mediated behavior, synaptic 
plasticity, and neurogenesis might be abnormal specifically 
in neuropathic pain, a clinical condition in which therapeutic 
approach is particularly challenging. The authors proposed 
that neuroplastic changes in animal models may be correlated 
with the reduction in hippocampal volume seen in chronic 
neuropathic pain patients. Moreover, they suggested that hip-
pocampal abnormalities may potentially underlie learning and 
emotional deficits commonly observed in patients affected by 
neuropathic pain.34
At present, very limited information is available on the 
potential mechanisms whereby chronic pain may affect hip-
pocampal neurogenesis and its behavioral consequences. It 
has been proposed that neuropathic pain induces a cluster 
of depressive-like symptoms and disrupts hippocampal 
plasticity via tumor necrosis factor receptor 1 (TNFR1) 
 signaling.35 When neuropathic pain was induced in mice by 
sciatic nerve chronic constriction injury (CCI), behavioral 
effects were associated with impaired hippocampal neuro-
genesis and reduced expression of several neuroplasticity 
markers. Temporally, the onset of depressive-like behavior 
coincided with increased hippocampal TNF levels and 
decreased expression of TNF R2. Notably, TNFR1−/− mice 
neither developed depressive-like symptoms after CCI nor 
developed changes in hippocampal neurogenesis and plas-
ticity, strongly suggesting a role of TNFR1-mediated TNF 
signaling as a possible regulator of these molecular, cellular, 
and behavioral events.35
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The distinct roles of ahNG in cognition and emotion have 
raised the interesting possibility that adult-born DG granule 
neurons may be functionally heterogeneous. The hippocampus 
is indeed anatomically and functionally dissociated along the 
dorsoventral (or septotemporal) axis. The dorsal (septal pole) 
hippocampus is more involved in spatial learning, navigation, 
and memory, while the ventral (temporal pole) hippocampus 
may mediate anxiety/depression-related behaviors. Similarly, 
adult-born neurons in the dorsal hippocampus appear to be 
required for acquisition of contextual discrimination, whereas 
those in the ventral hippocampus are required for emotional 
behavior.38,39 Cognitive behavioral therapy, such as EE and 
voluntary exercise (EE–VEx), is under investigation as a 
nonpharmacological approach for chronic pain. By using a 
mouse model of inflammatory pain, Zheng et al demonstrated 
a distinct contribution of ahNG along the dorsoventral axis to 
EE–VEx’s beneficial effects on different dimensions of chronic 
pain.37 Adult neurogenesis in the ventral hippocampus appeared 
to contribute to EE–VEx-mediated beneficial effects on per-
ceptual and affective components of chronic pain. Conversely, 
neurogenesis in the dorsal hippocampal pole was involved in 
EE–VEx cognitive-enhancing effects in chronic pain.37
As it always occurs in emerging and controversial research 
fields, recently Apkarian et al published an interesting paper 
which raised additional questions about the meaning of ahNG 
alterations in chronic pain states.40 The authors manipulated 
hippocampal neurogenesis by several different approaches 
(pharmacologically, by X-irradiation, and by the use of 
genetically modified mice displaying increased or decreased 
ahNG) and tested its influence on both inflammatory and 
neuropathic pain-like behaviors. Surprisingly, they reported 
that downregulation of ahNG reversibly diminished persistent 
pain, while upregulation resulted in prolonged persistent 
pain.40 Based on these findings, they actually proposed that 
ahNG-mediated learning mechanisms may be involved in the 
development of persistent pain.40 This is the first proposal of 
a potentially active role of neurogenesis in pain modulation. 
In light of these results, future studies should more carefully 
dissect the contribution of ahNG to development, mainte-
nance, and resolution of chronic pain states.
Table 1 List of preclinical studies showing reduced or deregulated ahNG in chronic pain states
Species Chronic pain model Effects on ahNG Additional observations Reference
Rat Inflammatory pain 
(CFA)
Reduced BrdU+ cells Similar to chronic immobilization stress 
effects 
Duric and McCarson32 
Mice (C57Bl/6) Neuropathic pain 
(SNL)
Suppressed proneurogenic 
effects of EE (reduced DCX+ and 
NeuroD+ neuroblasts)
No effect on basal ahNG Terada et al33
Mice (C57Bl/6;
DCX-EGFP 
mice)
Neuropathic pain 
(SNI) 
Reduction of DCX+/BrdU+ 
neuroblasts
Compared to sham animals, in SNI 
mice:
Altered short-term hippocampal 
synaptic plasticity
Inability to extinguish contextual fear 
and increased anxiety-like behavior
Mutso et al34
Mice
(C57Bl/6)
WT and 
TNFR1-/- mice 
Neuropathic pain
(CCI)
Reduced BrdU+/NeuN+ newly 
generated neurons in WT mice 
but not in TNFR1-/- mice
TNFR1-/- mice did not develop changes 
in hippocampal plasticity, and in 
parallel, depressive-like symptoms
No reduced neurogenesis in olfactory 
bulb
Dellarole et al35
Rat Neuropathic pain 
(CCI)
± chronic 
immobilization stress
Reduced proliferation, survival, 
and neuronal differentiation of 
newborn hippocampal cells 
Immobilization stress exacerbates the 
negative effect of neuropathic pain on 
ahNG
Romero-Grimaldi et al36
Mice
(C57Bl/6)
Inflammatory pain 
(CFA)
Reduced DCX+/BrdU+ neuroblasts
Reduced morphological complexity 
of newborn cells
Effects on ahNG alleviated by 
EE–VEx
Increasing ventral ahNG alleviates 
perceptual and affective components of 
chronic pain
Increasing dorsal ahNG alleviates 
cognitive impairment in chronic pain
Overexpression of BDNF in the DG 
mimicked the effects of EE–VEx
Zheng et al37
Abbreviations: ahNG, adult hippocampal neurogenesis; BDNF, brain-derived neurotrophic factor; BrdU, Bromodeoxyuridine; CCI, chronic constriction injury; CFA, 
complete Freund adjuvant; DCX, doublecortin; DG, dentate gyrus; EE, environmental enrichment; EE–VEx, environmental enrichment + voluntary exercise; NeuN, neuronal 
nuclear antigen; NeuroD, neurogenic differentiation 1; SNI, spared nerve injury; SNL, spinal nerve ligation; TNFR, tumor necrosis factor receptor; WT, wild-type.
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Potential clinical implications for 
deregulated ahNG in chronic pain 
states
Chronic pain is a highly debilitating disease state. Clini-
cal observations demonstrate that many patients affected 
by chronic pain exhibit increased anxiety and depression, 
suggesting the importance of affective or emotional pain 
components.41–43 Consistent with the concept of pain matrix, 
functional imaging studies also suggest that shared neural 
mechanisms may contribute to the comorbidity between 
chronic pain and anxiety/depression. In addition, there is 
clinical evidence that chronic pain may impair various aspects 
of cognition, including cognitive flexibility and memory 
capacities.44,45 Our current understanding of the molecular 
and cellular events that may underlie the comorbidity of 
chronic pain, depression, and cognitive impairment is still very 
limited. If and how persistent pain may affect potential brain 
areas, like the hippocampus, implicated in both cognition and 
emotional aspects has been largely unexplored. The occur-
rence of extensive preclinical evidence suggesting that chronic 
pain may induce profound changes in hippocampal plasticity, 
including deregulated hippocampal neurogenesis, should be 
further studied and addressed mechanistically. Based on a vast 
array of research observations, it is possible that dysregulated 
ahNG in chronic pain states may contribute, at least in part, 
to cognitive deficits and mood alterations in patients.
An additional aspect that should be taken into consider-
ation for its clinical implications is the different impact of 
distinct therapeutic interventions in chronic pain. Preclinical 
data mark the importance of taking into account inhibition of 
ahNG as a potential long-term consequence of some opiates. 
Indeed since the initial report,29 extensive experimental data 
have been accumulated on the negative impact of chronic 
morphine administration on ahNG mainly via µ-opioid 
receptors (MORs).31,46–51 The deleterious effect of morphine 
on hippocampal neurogenesis may potentially represent, 
among others, one mechanism by which morphine and other 
opiates exert long-lasting effects on the neural circuitries 
involved with cognition and mood regulation. Incidentally, 
cognitive dysfunction has been often reported in opiate drug 
abusers.48,52 Moreover, recent work has suggested an associa-
tion between prolonged opiate use and the risk of new onset 
depression.53,54 Interestingly though, some atypical opiates do 
not negatively influence adult NSC and their progeny, at least 
in preclinical models. An in vivo study in the rat reported that 
chronically administered methadone does not reduce ahNG.55 
Methadone is a strong opioid analgesic which, at  clinically 
achievable concentrations, can also inhibit functional 
N-methyl-d-aspartate (NMDA) receptors,56 and NMDA 
antagonists can produce positive effects on hippocampal 
neurogenesis in rodents.57,58 Whether this pharmacological 
property of methadone may explain its lack of negative 
effects on ahNG likely deserves further investigation. In a 
similar manner, tapentadol, the first representative of a novel 
analgesic drug class referred to as MOR-NRI (MOR agonist 
and noradrenaline reuptake inhibitor), did not reduce hippo-
campal neurogenesis when chronically administered in adult 
mice at a clinically relevant dose.59 It has been suggested that 
the noradrenergic component in tapentadol has the potential 
to counteract the adverse MOR-mediated effects on ahNG 
both in vivo and in vitro.59
Altogether, based on preclinical data, different risks of 
negative impact on ahNG are associated with distinct opiates 
which are commonly used in patients affected by chronic 
pain.31 At least in principle, the long-term use of analgesic 
drugs that do not cause dysfunction of ahNG may, in turn, 
result in less disruption of neurogenesis-associated functions 
in chronic pain patients. It should also be underlined that 
analgesic drugs which rather increase ahNG in preclinical 
models could be taken into consideration, at least in neuro-
pathic pain where they are very effective. Indeed, the a2δ 
ligands pregabalin/gabapentin61 and acetyl-l-carnitine62 have 
been demonstrated to significantly promote hippocampal 
neurogenesis in rodents. Interestingly, both drugs act via 
modulation of NF-κB-mediated signaling, a pathway that has 
been shown to play a crucial role in the regulation of ahNG 
in response to several signals and drugs.61–67 Interestingly, 
both a2δ ligands and acetyl-l-carnitine also exert antide-
pressant activity in rodent where depressive-like behavior 
was induced by chronic restraint or unpredictable chronic 
mild stress.61,62,68 Interestingly, the same drugs also produce 
antidepressant effects in patients.69,70 Again, at least in prin-
ciple, analgesic drugs that promote ahNG could represent first 
option therapy since they may have beneficial effects also on 
emotional and, potentially, on cognitive aspects in chronic 
pain states. At present, no clinical data are available to support 
this hypothesis since this approach would require to monitor 
neurogenesis in vivo, and no such imaging techniques are 
currently applicable in human studies. On the other hand, 
in vivo imaging of neurogenesis has been achieved in mice 
using transgenic model systems supporting the idea that in a 
near future detection of neurogenesis could theoretically be 
achieved in humans using current imaging devices.71
Altogether, based on several preclinical observations, 
in the future, more studies should be devoted to a better 
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 understanding of how analgesic drugs differentially affect 
molecular and cellular aspects of ahNG and hippocampal func-
tion. Currently, several compounds acting at different targets 
are under development for effective chronic pain treatment.72–74 
Potentially, future drug design may take into consideration the 
development of powerful analgesics that, by preserving or even 
promoting ahNG, may reduce the risk or prevent cognition and 
mood alterations in chronic pain patients.
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References
1. Kempermann G, Gast D, Kronenberg G, Yamaguchi M, Gage FH. 
Early determination and long-term persistence of adult-generated new 
neurons in the hippocampus of mice. Development. 2003;130:391–399.
2. Seri B, Garcia-Verdugo JM, Collado-Morente L, McEwen BS, Alvarez-
Buylla A. Cell types, lineage, and architecture of the germinal zone in 
the adult dentate gyrus. J Comp Neurol. 2004;478:359–378.
3. Bond AM, Ming GL, Song H. Adult mammalian neural stem cell and 
neurogenesis: five decades later. Cell Stem Cell. 2015;17(4):385–395.
4. Bergmann O, Spalding KL, Frisén J. Adult neurogenesis in humans. 
Cold Spring Harb Perspect Biol. 2015;7:a018994.
5. Shors TJ, Miesagaes G, Beylin A, Zhao M, Rydel T, Gould E. Neu-
rogenesis in the adult is involved in the formation of trace memories. 
Nature. 2001;410(6826):372–376.
6. Aimone JB, Wiles J, Gage FH. Potential role for adult neurogenesis in 
the encoding of time in new memories. Nat Neurosci. 2006;9:723–727.
7. Denis-Donini S, Dellarole A, Crociara P, et al. Impaired adult neu-
rogenesis associated with short-term memory defects in NF-kappaB 
p50-deficient mice. J Neurosci. 2008;28:3911–3919.
8. Deng W, Aimone JB, Gage FH. New neurons and new memories: how 
does adult hippocampal neurogenesis affect learning and memory? Nat 
Rev Neurosci. 2010;11:339–350.
9. Sahay A, Wilson DA, Hen R. Pattern separation: a common func-
tion for new neurons in hippocampus and olfactory bulb. Neuron. 
2011;70:582–588.
10. Aimone JB, Li Y, Lee SW, Clemenson GD, Deng W, Gage H. Regulation 
and function of adult neurogenesis: from genes to cognition. Physiol 
Rev. 2014;94:991–1026.
11. Kempermann G, Krebs J, Fabel K. The contribution of failing adult hip-
pocampal neurogenesis to psychiatric disorders. Curr Opin Psychiatry. 
2008;21(3):290–295.
12. Eisch AJ, Petrik D. Depression and hippocampal neurogenesis: a road 
to remission? Science. 2012;338:72–75.
13. Yun S, Reynolds RP, Masiulis I, Eisch AJ. Re-evaluating the link 
between neuropsychiatric disorders and dysregulated adult neurogen-
esis. Nat Med. 2016;22(11):1239–1247.
14. van Praag H, Shubert T, Zhao C, Gage F. Exercise enhances learn-
ing and hippocampal neurogenesis in aged mice. J Neurosci. 
2005;25(38):8680–8685.
15. Garthe A, Roeder I, Kempermann G. Mice in an enriched environment 
learn more flexibly because of adult hippocampal neurogenesis. Hip-
pocampus. 2016;26(2):261–271.
16. Mirescu C, Gould E. Stress and adult neurogenesis. Hippocampus. 
2006;16:233–238.
17. Schoenfeld TJ, Gould E. Stress, stress hormones, and adult neurogenesis. 
Exp Neurol. 2012;233:12–21.
18. Seib DR, Martin-Villalba A. Neurogenesis in the normal aging hip-
pocampus: a mini-review. Gerontology. 2015;61(4):327–335.
19. Duman RS, Nakagawa S, Malberg J. Regulation of adult neurogenesis 
by antidepressant treatment. Neuropsychopharmacology. 2001;25(6): 
836–844.
20. Malberg JE. Implications of adult hippocampal neurogenesis in antide-
pressant action. J Psych Neurosci. 2004;29(3):196–205.
21. Dranovsky A, Hen R. Hippocampal neurogenesis: regulation by stress 
and antidepressants. Biol Psych. 2006;59:1136–1143.
22. Bortolotto V, Cuccurazzu B, Canonico PL, Grilli M. NF-κB mediated 
regulation of adult hippocampal neurogenesis: relevance to mood dis-
orders and antidepressant activity. Biomed Res Int. 2014;2014:612798.
23. Boldrini M, Underwood MD, Hen R, et al. Antidepressants increase 
neural progenitor cells in the human hippocampus. Neuropsychophar-
macology. 2009;34(11):2376–2389.
24. Boldrini M, Hen R, Underwood MD, et al. Hippocampal angiogenesis 
and progenitor cell proliferation are increased with antidepressant use 
in major depression. Biol Psych. 2012;72(7):562–571.
25. Boldrini M, Santiago AN, Hen R, et al. Hippocampal granule neuron 
number and dentate gyrus volume in antidepressant-treated and untreated 
major depression. Neuropsychopharmacology. 2013;38(6):1068–1077.
26. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a con-
vergence of mechanisms. Neuropsychopharmacology. 2008;33:88–109.
27. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal 
neurogenesis for the behavioral effects of antidepressants. Science. 
2003;301(5634):805–809.
28. David DJ, Samuels BA, Rainer Q, et al. Neurogenesis-dependent and 
-independent effects of fluoxetine in an animal model of anxiety/depres-
sion. Neuron. 2009;62(4):479–493.
29. Eisch AJ, Barrot M, Schad CA, Self DW, Nestler EJ. Opiates inhibit 
neurogenesis in the adult rat hippocampus. Proc Natl Acad Sci U S A. 
2000;97(13):7579–7584.
30. Zhang Y, Loh HH, Law PY. Effect of opioid on adult hippocampal 
neurogenesis. Scientific World Journal. 2016;2016:2601264.
31. Bortolotto V, Grilli M. Opiate analgesics as negative modulators of adult 
hippocampal neurogenesis: potential implications in clinical practice. 
Front Pharmacol. 2017;8:254.
32. Duric V, McCarson KE. Persistent pain produces stress-like altera-
tion in hippocampal neurogenesis and gene expression. J Pain. 
2006;7(8):544–555.
33. Terada M, Kuzumaki N, Hareyama N, et al. Suppression of enriched 
environment-induced neurogenesis in a rodent model of neuropathic 
pain. Neurosci Lett. 2008;440(3):314–318.
34. Mutso AA, Radzicki D, Baliki MN, et al. Abnormalities in hippocampal 
functioning with persistent pain. J Neurosci. 2012;32(17):5747–5756.
35. Dellarole A, Morton P, Brambilla R, et al. Neuropathic pain- induced 
depressive like behavior and hippocampal neurogenesis and plasticity 
are dependent on TNFR1 signaling. Brain Behav Immun. 2014;41: 
65–81.
36. Romero-Grimaldi C, Berrocoso E, Alba-Delgado C, et al. Stress 
increases the negative effects of chronic pain on hippocampal neuro-
genesis. Anesth Analg. 2015;121(4):1078–1088.
37. Zheng J, Jiang YY, Xu LC, et al. Adult hippocampal neurogenesis 
along the dorsoventral axis contributes differentially to environmental 
enrichment combined with voluntary exercise in alleviating chronic 
inflammatory pain in mice. J Neurosci. 2017;37(15):4145–4157.
38. Tanti A, Belzung C. Neurogenesis along the septo-temporal axis of the 
hippocampus: are depression and the action of antidepressants region-
specific? Neuroscience. 2013;252:234–252.
39. O’Leary OF, Cryan JF. A ventral view on antidepressant action: roles 
for adult hippocampal neurogenesis along the dorsoventral axis. Trends 
Pharmacol Sci. 2014;35(12):675–687.
40. Apkarian AV, Mutso AA, Centeno MV, et al. Role of adult hippocampal 
neurogenesis in persistent pain. Pain. 2016;157(2):418–428.
41. MacWilliams LA, Cox BJ, Enns MW. Mood and anxiety disorders asso-
ciated with chronic pain: an examination in a nationally representative 
sample. Pain. 2003;106(1–2):127–133.
 
Jo
ur
na
l o
f P
ai
n 
Re
se
ar
ch
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
20
6.
49
.1
00
 o
n 
22
-O
ct
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Pain Research  2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Journal of Pain Research 
Publish your work in this journal
Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal 
The Journal of Pain Research is an international, peer reviewed, open 
access, online journal that welcomes laboratory and clinical findings 
in the fields of pain research and the prevention and management 
of pain. Original research, reviews, symposium reports, hypoth-
esis formation and commentaries are all considered for publication. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Dovepress
2286
Grilli
42. Baliki MN, Chialvo DR, Geha PY, et al. Chronic pain and the emotional 
brain: specific brain activity associated with spontaneous fluctuations of 
intensity of chronic back pain. J Neurosci. 2006;26(47):12165–12173.
43. Baliki MN, Apkarian AV. Nociception, pain, negative moods and 
behavior selection. Neuron. 2015;87(3):474–491.
44. Baker KS, Gibson S, Georgiou-Karistianis N, Roth RM, Giummarra 
MJ. Everyday executive functioning in chronic pain: specific deficits in 
working memory and emotional control, predicted by mood, medications 
and pain interference. Clin J Pain. 2016;32(8):673–680.
45. Moriarty O, Ruane N, O’Gorman D, et al. Cognitive impairment in 
patients with chronic neuropathic or radicular pain: an interaction of 
pain and age. Front Behav Neurosci. 2017;13(11):100.
46. Kahn L, Alonso G, Normand E, Manzoni OJ. Repeated morphine 
treatment alters polysialylated neural cell adhesion molecule, glutamate 
decarboxylase-67 expression and cell proliferation in the adult rat hip-
pocampus. Eur J Neurosci. 2005;21(2):493–500.
47. Mandyam CD, Norris RD, Eisch AJ. Chronic morphine induces prema-
ture mitosis of proliferating cells in the adult mouse subgranular zone. 
J Neurosci Res. 2004;76(6):783–794.
48. Eisch AJ, Harburg GC. Opiates, psychostimulants, and adult hip-
pocampal neurogenesis: insights for addiction and stem cell biology. 
Hippocampus. 2006;16(3):271–286.
49. Arguello AA, Harburg GC, Schonborn JR, Mandyam CD, Yamaguchi 
M, Eisch AJ. Time course of morphine’s effects on adult hippocampal 
subgranular zone reveals preferential inhibition of cells in S phase of 
the cell cycle and a subpopulation of immature neurons. Neuroscience. 
2008;157(1):70–79.
50. Fisher SJ, Arguello AA, Charlton JJ, Fuller DC, Zachariou V, Eisch AJ. 
Morphine blood levels, dependence, and regulation of hippocampal 
subgranular zone proliferation rely on administration paradigm. Neu-
roscience. 2008;151(4):1217–1224.
51. Zhang Y, Xu C, Zheng H, Loh HH, Law PY. Morphine modulates adult 
neurogenesis and contextual memory by impeding the maturation of 
neural progenitors. PLoS One. 2016;11(4):e0153628.
52. Canales JJ. Adult neurogenesis and the memories of drug addiction. Eur 
Arch Psychiatry Clin Neurosci. 2007;257(5):261–270.
53. Scherrer JF, Salas J, Lustman PJ, Burge S, Schneider FD; Residency 
Research Network of Texas (RRNeT) Investigators. Change in opioid 
dose and change in depression in a longitudinal primary care patient 
cohort. Pain. 2015;156(2):348–355.
54. Scherrer JF, Salas J, Copeland LA, et al. Increased risk of depression 
recurrence after initiation of prescription opioids in noncancer pain 
patients. J Pain. 2016;17(8):473–482.
55. Sankararaman A, Masiulis I, Richardson DR, Andersen JM, Mør-
land J, Eisch AJ. Methadone does not alter key parameters of adult 
hippocampal neurogenesis in the heroin-naïve rat. Neurosci Lett. 
2012;516(1):99–104.
56. Callahan RJ, Au JD, Paul M, Liu C, Yost CS. Functional inhibi-
tion by methadone of N-methyl-D-aspartate receptors expressed in 
Xenopus oocytes: stereospecific and subunit effect. Anesth Analg. 
2004;98(3):653–659.
57. Nacher J, Rosell DR, Alonso-Llosa G, McEwen BS. NMDA receptor 
antagonist treatment induces a long-lasting increase in the number 
of proliferating cells, PSA-NCAM-immunoreactive granule neu-
rons and radial glia in the adult rat dentate gyrus. Eur J Neurosci. 
2001;13(3):512–520.
58. Maekawa M, Namba T, Suzuki E, Yuasa S, Kohsaka S, Uchino S. 
NMDA receptor antagonist memantine promotes cell proliferation 
and production of mature granule neurons in the adult hippocampus. 
Neurosci Res. 2009;63(4):259–266.
59. Tzschentke TM, Christoph T, Kögel B, et al. (-)-(1R,2R)-3-(3-dimeth-
ylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol 
HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake 
inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp 
Ther. 2007;323(1):265–276.
60. Meneghini V, Cuccurazzu B, Bortolotto V, et al. The noradrenergic compo-
nent in tapentadol action counteracts µ-opioid receptor-mediated adverse 
effects on adult neurogenesis. Mol Pharmacol. 2014;85(5):658–670.
61. Valente V, Bortolotto V, Cuccurazzu B, et al. a2δ ligands act as positive 
modulators of adult hippocampal neurogenesis and prevent depression-
like behavior induced by chronic restraint stress. Mol Pharmacol. 
2013;82(2):271–280.
62. Cuccurazzu B, Bortolotto V, Valente MM, et al. Upregulation of mGlu2 
receptors via NF-κB p65 acetylation is involved in the Proneurogenic 
and antidepressant effects of acetyl-L-carnitine. Neuropsychopharma-
cology. 2013;38(11):2220–2230.
63. Meneghini V, Bortolotto V, Francese MT, et al. High-mobility group 
box-1 protein and β-amyloid oligomers promote neuronal differentia-
tion of adult hippocampal neural progenitors via receptor for advanced 
glycation end products/nuclear factor-κB axis: relevance for Alzheimer’s 
disease. J Neurosci. 2013;33(14):6047–6059.
64. Valente MM, Allen M, Bortolotto V, et al. The MMP-1/PAR-1 axis 
enhances proliferation and neuronal differentiation of adult hippocampal 
neural progenitor cells. Neural Plast. 2015;2015:646595.
65. Bortolotto V, Grilli M. Every cloud has a silver lining: proneurogenic 
effects of Aβ oligomers and HMGB-1 via activation of the RAGE-
NF-κB axis. CNS Neurol Disord Drug Targets. Epub 2016 Aug 3.
66. Cvijetic S, Bortolotto V, Manfredi M, et al. Cell autonomous and 
noncell-autonomous role of NF-κB p50 in astrocyte-mediated fate 
specification of adult neural progenitor cells. Glia. 2017;65(1):169–181.
67. Bortolotto V, Mancini F, Mangano G, et al. Proneurogenic effects of 
trazodone in murine and human neural progenitor cells. ACS Chem 
Neurosci. Epub 2017 Jul 3.
68. Nasca C, Xenos D, Berone Y, et al. L-acetylcarnitine causes rapid anti-
depressant effects through the epigenetic induction of mGlu2 receptors. 
Proc Natl Acad Sci  U S A. 2013;110(12):4804–4809.
69. Pae CU. Pregabalin augmentation to antidepressants in patients with 
major depressive disorder. Prog Neuropsychopharmacol Biol Psychia-
try. 2009;33(3):577–578.
70. Bersani G, Meco G, Denaro A, et al. L-acetylcarnitine in dysthymic 
disorder in elderly patients: a double-blind, multicenter, controlled 
randomized study vs. fluoxetine. Eur Neuropsychopharmacol. 
2013;23(10):1219–1225.
71. Ortega F, Costa MR. Live imaging of adult neural stem cells in rodents. 
Front Neurosci. 2016;10:78.
72. Sasikumar TK, Qiang L, Burnett D, et al. A-ring modifications on the 
triazafluorenone core structure and their mGluR1 antagonist properties. 
Bioorg Med Chem Lett. 2010;20:2474–2477.
73. Chang DS, Raghavan R, Christiansen S, Cohen SP. Emerging targets in 
treating pain. Curr Opin Anaesthesiol. 2015;28(4):379–397.
74. Yaksh TL, Woller SA, Ramachandra R, Sorkin LS. The search of novel 
analgesics: targets and mechanisms. F1000Prime Rep. 2015;7:56.
 
Jo
ur
na
l o
f P
ai
n 
Re
se
ar
ch
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
20
6.
49
.1
00
 o
n 
22
-O
ct
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
